NovoCure Limited (NVCR)

NasdaqGS • Currently down 0.27 (-1.99%) in today's trading session

2 members of Congress have disclosed 5 trades in NovoCure Limited (NVCR) via STOCK Act filings. The most recent disclosure was a purchase by Marie Newman on 2 July 2021. The most active traders have been Donna E. Shalala (4) and Marie Newman (1). Aggregate disclosed activity totals roughly $48.5K in purchases and $16K in sales (midpoint estimates from bracketed disclosure amounts).

NovoCure Limited is currently trading at $13.28, positioned at 30% of its 52-week range ($9.82 – $21.45).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$13.28
24h Change
-0.27 (-1.99%)
52 Week Range
$9.82–$21.45
View on NASDAQ

NovoCure Limited Price History and Technical Analysis

Congressional Trading Activity for NVCR

Select to highlight on chart
5 transactions
Compliance: 60%
Marie Newman2 Jul 20215 Aug 2021PurchaseStock$15,001 - $50,000N/A
Donna E. Shalala24 Jun 201927 Apr 2020SaleStock$1,001 - $15,000N/A
Donna E. Shalala24 Jun 201921 Jul 2020SaleStock$1,001 - $15,000N/A
Donna E. Shalala19 Jun 201927 Apr 2020PurchaseStock$1,001 - $15,000N/A
Donna E. Shalala19 Jun 201921 Jul 2020PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$1.55B

Volume

1.14M

Beta

1.08

P/E Ratio

-12.53

Fundamentals

EPS

$-1.06

Div. Yield

-

Open

$13.52

Day Range

$13.06 – $13.59

Company Information

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ · USD
Country
CH
CEO
Frank Leonard
IPO Date
2015-10-02
Website
www.novocure.com

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...

Earnings

Next Report

Q4 2026

25 Feb

EPS Est.

$-0.21

Rev. Est.

$190.2M

Days Until

108

Recent Quarters

Q3 202629 Oct
EPS$-0.09
Beat 61.7%
Q2 202623 Jul
EPS$-0.13
Beat 60.8%
Q1 202630 Apr
EPS$-0.62
Miss 21.1%
Q4 202526 Feb
EPS$-0.22
Beat 46.3%
Q3 202530 Oct
EPS$-0.33
Beat 21.4%
Q2 202524 Jul
EPS$-0.36
Beat 7.7%
Q1 202524 Apr
EPS$-0.31
Beat 34.0%
Q4 202427 Feb
EPS$-0.61
Miss 79.4%
Q3 202430 Oct
EPS$-0.28
Beat 17.6%
Q2 202425 Jul
EPS$-0.31
Beat 22.5%
Q1 20242 May
EPS$-0.36
Beat 16.3%
Q4 202322 Feb
EPS$-0.45
Beat 15.1%
Q3 202326 Oct
EPS$-0.46
Beat 11.5%
Q2 202327 Jul
EPS$-0.54
Miss 8.0%
Q1 20234 May
EPS$-0.50
Miss 38.9%
Q4 202223 Feb
EPS$-0.36
Miss 12.5%
Q3 202227 Oct
EPS$-0.25
Beat 16.7%
Q2 202228 Jul
EPS$-0.23
Miss 64.3%
Q1 202228 Apr
EPS$-0.04
Beat 76.5%
Q4 202124 Feb
EPS$-0.25
Miss 150.0%
Q3 202128 Oct
EPS$-0.13
Miss 116.7%
Q2 202129 Jul
EPS$-0.14
Miss 1674.4%
Q1 202129 Apr
EPS$-0.04
Miss 300.0%
Q4 202025 Feb
EPS$0.04
Miss 66.7%
Q3 202029 Oct
EPS$0.09
Beat 170.0%
Q2 202030 Jul
EPS$0.02
Q1 202030 Apr
EPS$0.04
Beat 86.7%
Q4 201927 Feb
EPS$0.04
Beat 154.6%
Q3 201931 Oct
EPS$0.02
Beat 140.0%
Q2 201925 Jul
EPS$-0.01
Beat 85.7%
Q1 20192 May
EPS$-0.13
Beat 0.0%
Q4 201828 Feb
EPS$-0.17
Miss 13.3%
Q3 201825 Oct
EPS$-0.13
Beat 13.3%
Q2 201826 Jul
EPS$-0.17
Miss 13.3%
Q1 201826 Apr
EPS$-0.23
Miss 76.9%
Q4 201722 Feb
EPS$-0.12
Beat 14.3%
Q3 201726 Oct
EPS$-0.13
Beat 35.0%
Q2 201727 Jul
EPS$-0.24
Miss 4.3%
Q1 201727 Apr
EPS$-0.21
Beat 16.0%
Q4 201623 Feb
EPS$-0.26
Beat 35.0%
Q3 20162 Nov
EPS$-0.39
Beat 9.3%
Q2 201628 Jul
EPS$-0.48
Miss 23.1%
Q1 20169 May
EPS$-0.42
Miss 40.0%
Q4 201529 Feb
EPS$2.54
Beat 893.8%
Q3 201526 Oct
EPS$-2.09
Q3 201519 Oct
EPS$-0.36
Q4 201431 Mar
EPS$-0.32
Q3 201431 Dec
EPS$-0.32
Q2 201430 Sept
EPS$-0.25
Q1 201430 Jun
EPS$-1.71
Q4 201331 Mar
EPS$-1.50

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

R

Ryder System, Inc.

17
$266.39-3.77 (-1.40%)
Industrials
Held by same politician
1 politician
View Stock

MSFT

Microsoft Corporation

17
$530.61-5.32 (-0.99%)
Technology
Held by same politician
1 politician
View Stock

NFLX

Netflix, Inc.

17
$63.41-2.15 (-3.28%)
Communication Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about NVCR

Which members of Congress have traded NVCR?
2 members of Congress have disclosed 5 trades in NovoCure Limited (NVCR) under the STOCK Act. The most active traders are Donna E. Shalala and Marie Newman.
When was NVCR most recently disclosed by Congress?
The most recent NVCR disclosure was a purchase by Marie Newman on 2 July 2021.
What is the total disclosed congressional trading volume for NVCR?
Members of Congress have disclosed approximately $48.5K in NVCR purchases and $16K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in NVCR?
This NVCR page updates as soon as new STOCK Act disclosures are filed for NovoCure Limited. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.